A One-Year, Single-Center, Prospective, Open-Label Study of the Safety, Tolerability, and Preliminary Efficacy of Anti-Thymocyte Globulin, Cyclosporine, and RAD in Type 1 Diabetic Islet Transplant Recipients.

Trial Profile

A One-Year, Single-Center, Prospective, Open-Label Study of the Safety, Tolerability, and Preliminary Efficacy of Anti-Thymocyte Globulin, Cyclosporine, and RAD in Type 1 Diabetic Islet Transplant Recipients.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Dec 2009

At a glance

  • Drugs Antithymocyte globulin; Ciclosporin; Everolimus
  • Indications Islet cell transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Aug 2007 Status change from in progress to completed.
    • 03 Dec 2006 Status change
    • 11 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top